Evidências na literatura apontam o núcleo basolateral do complexo amigdalóide como uma estrutura importante na elaboração e controle das respostas defensivas. O sistema serotonérgico é um dos tantos sistemas de neurotransmissão que estão envolvidos nessas respostas. Dentre os diferentes subtipos de receptores serotonérgicos existentes, os do tipo 5-HT2C é um dos mais estudados com relação à mediação dos processos de ansiedade. A estimulação de receptores 5-HT2C tem efeito do tipo ansiogênico em diferentes modelos animais de ansiedade. Porém, não se conhece ainda a real participação desses receptores localizados no núcleo basolateral do complexo amigdalóide sobre as respostas de esquiva e fuga geradas no labirinto em T elevado relacionas, respectivamente, com ansiedade generalizada e pânico. Assim, o presente trabalho teve por objetivo verificar o papel dos receptores serotonérgicos do tipo 5-HT2C do núcleo basolateral do complexo amigdalóide na modulação das respostas defensivas associadas à ansiedade generalizada e ao pânico. Foram realizadas injeções bilaterais intra-núcleo basolateral do agonista endógeno serotonina, do agonista preferencial de receptores 5-HT2C MK-212 ou do antagonista seletivo desses receptores SB242084 em ratos submetidos ao teste do labirinto em T elevado e teste de transição claro-escuro. Os resultados mostram que a administração do agonista endógeno serotonina e do agonista de receptores do tipo 5-HT2C MK-212 promove uma facilitação na aquisição da esquiva inibitória em ratos testados no labirinto em T elevado. A administração dos agonistas também diminui o tempo gasto pelos animais no compartimento claro da caixa claro-escuro, também sugerindo um efeito do tipo ansiogênico. Por outro lado, a administração local do antagonista dos receptores 5-HT2C SB-242084 prejudica tal resposta. Esse mesmo tratamento não altera a resposta no teste de transição claro-escuro. A administração prévia de SB-242084 é capaz de bloquear o efeito ansiogênico promovido pela serotonina. Nem a ativação nem o bloqueio desses receptores exerceu efeito sobre a resposta de fuga. Em suma, nossos resultados sugerem que os receptores 5-HT2C do núcleo basolateral do complexo amigdalóide têm papel regulatório sobre a resposta de esquiva inibitória, mas não sobre a resposta de fuga gerada no labirinto em T elevado. / A wealth of evidence highlights the importance of serotonergic mechanisms within the basolateral nucleus of the amygdala for the regulation of defensive responses. However, conflicting evidence exists on the role of played by different 5-HT receptor subtypes such as 5-HT1A, 5-HT2A and 5-HT2C receptors in this process. For instance, previous studies show that whereas activation of the former two subtypes causes anxiolytic-like effect in the elevated T-maze, stimulation of 5-HT2C receptors has anxiogenic consequences in different animal models of anxiety. In this study we further explored the role played by 5-HT2C receptors of the basolateral nucleus of the amygdala in the regulation of defensive behaviors that have been associated with generalized anxiety and panic. The results showed that bilateral injection of the endogenous agonist serotonin or the 5-HT2C receptor agonist MK-212 facilitates inhibitory avoidance acquisition in rats tested in the elevated T-maze. Both drugs decreased the time spent by the animals in the light compartment of a light-dark box, also suggesting an anxiogenic-like effect. On the other hand, local administration of the 5-HT2C receptor antagonist SB-242084 impaired inhibitory avoidance acquisition in the elevated T-maze, but was without effect upon the behaviors measured in the light-dark transition test. Previous administration of SB-242084 blocked the anxiogenic effect of serotonin on inhibitory avoidance acquisition in the T-maze. Neither the blockade nor the activation of 5-HT2C receptors of the basolateral nucleus of the amygdala affected escape performance in the elevated T-maze. In summary, the results obtained in the present study are indicative that 5-HT2C receptors in the basolateral nucleus of the amygdala are selectively involved in the regulation of defensive behaviors that are associated with generalized anxiety but not panic disorder.

Diss. (sammanfattning) Stockholm : Karol. inst., 2006. / Härtill 4 uppsatser.

No description available.

No description available.

Yes / Rationale: 5-HT receptor mechanisms have been suggested to mediate improvements in cognition in schizophrenia. Aim: To investigate the involvement of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in female rats, a task of relevance to schizophrenia. Methods: Adult female hooded-Lister rats were trained to perform an operant reversal learning task and then received sub-chronic PCP (2 mg/kg) or vehicle i.p. twice daily for seven days, followed by 7-days washout. Rats then received an acute dose of the 5-HT7 receptor antagonist SB-269970A (1.0, 3.0, 10.0 mg/kg; i.p.) or vehicle. In experiment 2, PCP-treated rats received the selective 5-HT2C receptor antagonist, SB-243213A acutely (1.0, 3.0, 10.0 mg/kg; i.p.) or vehicle. In experiment 3, PCP-treated rats received the 5-HT1A receptor partial agonist, buspirone (0.15625, 0.3125, 0.625 mg/kg, i.p.) in combination with the selective 5-HT1A receptor antagonist WAY-100635 (0.3, 1.0 mg/kg). Results: In all experiments sub-chronic PCP significantly impaired reversal phase performance (P<0.01-0.001), with no effect in the initial phase. SB-269970A at 3.0 and 10.0 mg/kg significantly improved the PCP-induced deficit (P<0.05). SB-243213A also significantly attenuated the deficit at 10 mg/kg (P<0.05). In experiment 3, buspirone attenuated the deficit with significant effects at 0.3125 mg/kg and 0.625 mg/kg (P<0.05). WAY-100635 at 0.3 and 1.0 mg/kg produced a partial attenuation of buspirone’s effect as buspirone (0.3125 mg/kg) in the presence of WAY-100635 did not significantly reverse the PCP-induced deficit. Conclusions: These studies implicate the role of 5-HT7, 5-HT2C and 5-HT1A receptors in the improvement of cognitive dysfunction of relevance to schizophrenia.

La mort soudaine inattendue (SUDEP) est fréquemment rapportée chez les patients qui souffrent d'épilepsie et compte pour près de 17% des décès dans cette population. Bien que son étiologie soit restée longtemps incertaine, des études menées sur des cas de victimes de SUDEP suggèrent fortement l'implication de l'apnée post-ictale dans la survenue de ce type de décès. Afin d'élucider les mécanismes physiopathologique de la SUDEP, il était nécessaire de mettre en place un modèle animal qui présente à la fois des crise spontanées récurrentes comme dans le syndrome épileptique et des altérations respiratoires. Dans une première partie, nous mettons en évidence la présence d'altérations respiratoires (RAs) chez 30 à 50% des rats qui présentent une épilepsie suite à un état de mal épileptique (SE) induit par l'administration de pilocarpine. Ces RAs, que nous avons assimilées à des apnées, ont été mises en évidence par thermochimie respiratoire et se traduisent par une diminution de la consommation en oxygène, dont la durée peut varier entre 20 secondes et 13 minutes. La présence des RAs est associée à des altérations du système sérotoninergique au niveau du tronc cérébral, où sont concentrés la majorité des groupes de neurones impliqués dans la régulation et dans la modulation de la fonction respiratoire. Nous montrons que de nombreux gènes du système sérotoninergique sont dérégulés lors de la mise en évidence des RAs ; toutefois, seules les altérations touchant le récepteur 5-HT2c semblent être associées au maintien des RAs. Ce résultat est d'autant plus important qu'il avait été montré que la délétion de ce récepteur chez les souris peut conduire à un arrêt respiratoire fatal suite à une crise épileptique, provoquée ou spontanée. Dans une seconde partie, nous montrons que la surface de la zone présentant un hypersignal T2 dans le système limbique ventral des rats épileptiques est prédictive de la présence de RAs. En outre, des différences d'expression du récepteur 5-HT2c similaires à celles qui avaient été observées dans le tronc cérébral sont retrouvées entre les rats épileptiques selon qu'ils présentent ou pas des RAs. Les résultats de cette thèse impliquent donc le récepteur 5-HT2c dans la survenue et/ou le maintien des altérations respiratoires associées à l'épilepsie. Dans le contexte de la SUDEP, nos résultats ouvrent comme première perspective clinique celle de développer des traitements permettant de cibler spécifiquement le récepteur 5-HT2c chez les patients qui présenteraient un risque de survenue de la SUDEP. La seconde perspective clinique serait de pouvoir identifier ces patients à risque à partir de biomarqueurs tels que les anomalies de signal T2 que nous avons identifiées dans la région limbique ventrale qui inclut notamment l'insula, dont il a été montré qu'elle contribue à la modulation de la fonction respiratoire / Pas de résumé anglais

La dépression est l’un des troubles mentaux les plus fréquents de nos jours. C’est une maladie liée en général à un déficit en neurotransmetteurs monoaminergiques (sérotonine, noradrénaline et dopamine). Les antidépresseurs actuels agissant via des mécanismes monoaminergiques présentent de nombreux effets secondaires et peuvent conduire à une accoutumance. L’une des approches impliquerait le ciblage des récepteurs mélatoninergiques afin de resynchroniser les rythmes circadiens qui sont perturbés dans certaines pathologies du système nerveux central, notamment la dépression. La conception de ligands non monoaminergiques et possédant des propriétés chronobiotiques constituerait une stratégie prometteuse.L’agomélatine (Valdoxan®) issue d’une collaboration entre le laboratoire de chimie thérapeutique (EA4481 - GRIIOT) et les laboratoires Servier est commercialisée depuis 2009 pour le traitement de la dépression majeure. Ce bioisoster naphtalénique de la mélatonine possède un mécanisme d’action innovant. Elle se distingue par ses propriétés agoniste non sélectif des récepteurs mélatoninergiques MT1 et MT2 et antagoniste des récepteurs 5-HT2c.L’objectif de ce travail réside dans la conception et la synthèse de nouveaux ligands successeurs de l’agomélatine présentant un profil pharmacologique et pharmacocinétique amélioré. Différentes pharmacomodulations ont été réalisées sur l’agomélatine. Les stratégies de «Drug Design» notamment le principe de bioisostérie ont été appliquées, nous permettant ainsi la synthèse de nouvelles familles de composés présentant des profils pharmacologiques intéressants. / Nowadays, depression related to a deficit in nonoaminergic neurotransmitters, is the most frequent mental illness. Available antidepressive drugs acting through monoamnergic mechanisms possess a lot of side effects and can lead to an addiction. One approach involves targeting melatoninergic receptors to resynchronize circadian rhythms, which are known to be perturbed in some pathology related to nervous central system as depression. So conception of non-monoaminergic ligands with chronobiotic properties would constitute a promising strategy.Agomelatine (Valdoxan®) a novel antidepressant developed by Servier and our laboratory (EA4481 - GRIIOT) was granted marketing authorization in 2009 for the treatment of major depressive disorder. This naphthalen analogous of melatonin possess an innovative mechanism. It acts as a non selective melatoninergic MT1/MT2 receptors agonist and a serotonin 5-HT2c receptor antagonist.The aim of this work is to design and synthesize new potential successors of agomelatine with an improved pharmacological and pharmacokinetic profile. Drug Design strategies such as bioisosterism were applied to allow the elaboration of new series of compounds with interesting pharmacological profiles.

Submitted by Izabel Franco (izabel-franco@ufscar.br) on 2016-09-15T15:07:42Z No. of bitstreams: 1 DissEMFC.pdf: 1127581 bytes, checksum: a37fcb5548575f25ebe36ee92d664535 (MD5) / Approved for entry into archive by Marina Freitas (marinapf@ufscar.br) on 2016-09-16T19:26:53Z (GMT) No. of bitstreams: 1 DissEMFC.pdf: 1127581 bytes, checksum: a37fcb5548575f25ebe36ee92d664535 (MD5) / Approved for entry into archive by Marina Freitas (marinapf@ufscar.br) on 2016-09-16T19:27:10Z (GMT) No. of bitstreams: 1 DissEMFC.pdf: 1127581 bytes, checksum: a37fcb5548575f25ebe36ee92d664535 (MD5) / Made available in DSpace on 2016-09-16T19:27:21Z (GMT). No. of bitstreams: 1 DissEMFC.pdf: 1127581 bytes, checksum: a37fcb5548575f25ebe36ee92d664535 (MD5) Previous issue date: 2014-05-08 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Neuropathic pain is a type of chronic pain that can causes comorbidities such as generalized anxiety and depression, and, consequently, it produces considerable damage to the quality of life of affected people. Despite it being refractory to most conventional pharmacological treatments, studies evidence that serotonergic drugs, like antidepressants, are effective in treatment of this type of pain. Serotonin is a neurotransmitter with an important role in the modulation of nociceptive stimuli as well as the behaviors related to fear and anxiety. There is evidence that aversive situations, such as predator exposure may cause antinociception as a defensive reaction. Thus, several studies have demonstrated that fear or anxiety stimulus can cause antinociception and the serotonin (5-HT) produces this antinociceptive effect in structures of the central nervous system, such as the periaqueductal gray matter (PAG). In this sense, studies from our group demonstrate that activation of 5-HT2C receptors in PAG is involved in anxiolytic effects and in fear and anxiety-induced antinociception in mice exposed to the elevated plus maze. However, it is unknown what the role of PAG serotonergic receptors in the modulation of antinociception induced by exposure to predator (rat). Thus, the objective of this study was to evaluate the effect of activation of 5-HT2C receptors of PAG on the antinociception and defensive behaviors in mice submitted to sciatic nerve constriction. For this, Swiss-albino male mice were submitted to sciatic nerve constriction on the first day of the experiment and, seven days later, they received implantation of guide cannula in the PAG. Four days after stereotactic surgery, mice received intra-PAG injection of vehicle or mK212 and were exposed to the predator. The test consisted of two phases: a) habituation to the apparatus for 10 minutes for 3 consecutive days, which started the next day after stereotactic surgery; b) exposure to predators or neutral stimulus for 10 minutes. The analysis of variance (ANOVA) of three factors (condition x stimulation x treatment) showed that chronic constrition injured (CCI) mice exhibited increased of scratching behavior, that is indicative of chronic pain. The exposure of these animals to the predator (rat) produced antinociception in CCI mice and increased behaviors related to fear and anxiety such as time spent in protected area and total number of stretched attend posture (SAP) and decreased time of contact with the grid, when compared to mice exposed to neutral stimulus (toy rat). Treatment with mK212 intra-PAG (0.21 and 0.63 nmol) produced no significant change in antinociception and fear and anxiety assessed during exposure to rat. However, the mK212 0.21nmol dose treatment increased scratching behavior, indicating hyperalgesia in CCI mice exposed to toy rat. Thus, we suggest that 5-HT2C receptors of PAG appear to modulate differently this type of antinociception and fear and anxiety in mice. However, further studies should be conducted using more selective subtypes of serotonergic receptors and perhaps other models of nociception to enlarge and clarify the role of 5-HT2C receptors in the processes that modulate antinociception induced by aversive stimuli. / A dor neuropática é um tipo de dor crônica que pode ocasionar comorbidades como a ansiedade e a depressão e, consequentemente, grandes prejuízos a qualidade de vida da população atingida. Apesar de ser refratária a maioria dos tratamentos farmacológicos convencionais, há estudos que descrevem a eficácia dos medicamentos que atuam na transmissão serotonérgica, como os antidepressivos, no tratamento da dor neuropática. A serotonina é um neurotransmissor com papel importante na modulação dos estímulos nociceptivos, assim como dos comportamentos relacionados ao medo e a ansiedade. Há evidências de que situações aversivas, como a exposição ao predador, podem causar antinocicepção como reação defensiva. Dessa forma, vários trabalhos têm demonstrado que situações de geram medo/ansiedade, podem inibir a nocicepção e a serotonina (5-HT) produz esse efeito antinociceptivo em estruturas do sistema nervoso central, tais como a substância cinzenta periaquedutal (SCP). Neste sentido, estudos do nosso grupo mostraram que a ativação dos receptores 5-HT2C da SCP está envolvida nos efeitos ansiolíticos e na antinocicepção induzida pelo medo/ansiedade observados em camundongos expostos ao labirinto em cruz elevado. Entretanto não se conhece qual o papel desses receptores da SCP na modulação da antinocicepção induzida pela exposição ao predador (rato) em camundongos. Assim, o objetivo deste trabalho foi avaliar o efeito da ativação dos receptores 5-HT2C da SCP, sobre a antinocicepção e as respostas defensivas em camundongos submetidos a constrição do nervo ciático. Para isso, camundongos machos Suiço-albinos foram submetidos a constrição do nervo ciático (CNC) no primeiro dia do experimento e, sete dias depois, receberam implantação de cânula guia na SCP. Quatro dias após a estereotaxia, os camundongos receberam microinjeção de veículo ou mK212 e foram expostos ao predador. O teste consistiu em duas fases: a) habituação ao aparato, durante 10 minutos, por 3 dias consecutivos, iniciado no dia seguinte após a estereotaxia; b) exposição ao predador ou ao estímulo neutro durante 10 minutos. Os resultados obtidos após passarem pela análise de variância (ANOVA) de três fatores (condição x estímulo x tratamento), mostraram que os camundongos que passaram por CNC exibiram aumento do reflexo de coçar, comportamento indicativo de dor crônica. A exposição desses animais ao predador (rato) produziu antinocicepção nos camundongos CNC e aumentou os comportamentos relacionados ao medo/ansiedade tais como, tempo de permanência na área protegida e em contato com a grade e frequência de esticar, quando comparados aos camundongos expostos ao estímulo neutro (rato de brinquedo). O tratamento intra-SCP com mK212 (0,21 e 0,63nmol) não produziu alterações significativas na antinocicepção e no medo/ansiedade avaliados durante a exposição ao rato. Entretanto, apenas a menor dose de mK212 (0,21nmol) foi capaz de aumentar o reflexo de coçar, produzindo hiperalgesia nos camundongos CNC expostos ao estímulo neutro. Desta forma, sugerimos que os receptores 5-HT2C da SCP parecem modular de forma diferenciada este tipo de antinocicepção e medo/ansiedade em camundongos. Porém novos estudos devem ser realizados, utilizando subtipos de receptores mais seletivos e talvez outros modelos de nocicepção para ampliar e esclarecer o papel dos receptores 5-HT2C nos processos que modulam a antinocicepção induzida por estímulos aversivos.

Los trastornos emocionales de tipo depresivo y la ansiedad son las formas más prevalentes de enfermedad mental y suponen un serio problema de salud en la sociedad occidental. Recientemente, se ha postulado que el sistema endocannabinoide pueda ser un importante sustrato en el desarrollo de estos trastornos dada su participación en el control de las emociones. Nuestros resultados demuestran que los animales carentes del receptor cannabinoide CB1 manifiestan un fenotipo de tipo depresivo asociado a una deficiencia del factor neurotrófico BDNF en el hipocampo, que podría estar causada por los elevados niveles de glucocorticoides liberados en respuesta al estrés en estos mutantes. Por otra parte, el sistema endocannabinoide participa en los efectos inducidos por la nicotina sobre la ansiedad y en la expresión del síndrome de abstinencia de esta droga. Así, la actividad del receptor CB1 alivia los efectos ansiogénicos de dosis elevadas de nicotina y facilita los efectos ansiolíticos de dosis bajas. Además, la administración del agonista cannabinoide &#61508;9-THC atenúa las manifestaciones somáticas y emocionales negativas de la abstinencia de nicotina. En general, considerando los resultados presentados en esta Tesis Doctoral, podemos afirmar que el receptor CB1 participa de forma determinante en la recuperación del balance homeostático del organismo tras la exposición a un estímulo emocional negativo, bien sea una situación estresante aguda o sostenida, o bien una droga que incrementa los niveles de ansiedad o cuya retirada produce abstinencia. / Mood disorders such as depression and anxiety are the most common mental diseases and they suppose a serious health problem in our society. Recently, endocannabinoid system has been postulated to be an important substrate in the development of such disorders taking into account the role exerted by this neuromodulatory system in mood and emotions. Our results demonstrate that CB1 knockout mice exhibit a depressive-like phenotype associated to a deficiency in the neurotrophic factor BDNF in the hippocampus, which could be a consequence of the increased glucocorticoid release in response to stress exposure. On the other hand, the endocannabinoid system participates in nicotine induced effects on anxiety and in the expression of nicotine withdrawal. Thus, CB1 receptor activity attenuates anxiogenic-like effects and facilitates anxiolytic-like responses induced by high or low doses of nicotine, respectively. Moreover, &#61508;9-THC administration ameliorates somatic and negative motivational signs of nicotine withdrawal. In summary, the results presented in this Doctoral Thesis indicate that CB1 receptor participates in the recovery of the homeostatic balance after the exposure to negative emotional stimuli, either acute or sustained stress or a drug which induced anxiety-like effects or withdrawal signs after the end of the exposure.